Terbinafine Use with Moderate Renal Impairment
Terbinafine has not been adequately studied in patients with renal impairment (creatinine clearance ≤50 mL/min) and should be avoided in this patient, despite the normal liver enzymes. 1
Critical Safety Concern: Renal Impairment
Your patient has an eGFR of 50 mL/min/1.73 m², which places them at the exact threshold where the FDA label explicitly states terbinafine "has not been adequately studied." 1 This is a hard contraindication based on lack of safety data, not just a precaution.
Why This Matters
- Terbinafine clearance decreases by approximately 50% in patients with creatinine clearance ≤50 mL/min 1
- The drug is cleared mostly by the kidney (approximately 70% eliminated in urine) 2, 1
- Reduced clearance leads to drug accumulation, increasing risk of adverse effects
- There is documented risk of rhabdomyolysis with acute kidney injury requiring dialysis in previously healthy patients on terbinafine 3
Liver Function Assessment
The liver enzymes (ALT 41, AST 46, ALP 52) are essentially normal and would not independently contraindicate terbinafine. The British Association of Dermatologists guidelines note that terbinafine is contraindicated in active or chronic liver disease, not mild enzyme elevations 2. However, this is irrelevant given the renal impairment.
Recommended Alternative: Fluconazole
Consider fluconazole as the preferred alternative for this patient with moderate renal impairment 2:
- Dose adjustment is straightforward: Fluconazole dose can be adjusted based on creatinine clearance 2
- Once-weekly dosing: 150-450 mg per week improves compliance
- Duration: 3 months for fingernails, at least 6 months for toenails 2
- Monitoring: Baseline liver function tests and complete blood count; monitor LFTs during prolonged therapy 2
Alternative Consideration: Itraconazole
Itraconazole is another option, though it requires careful monitoring:
- No specific renal dose adjustment mentioned in guidelines
- Pulse therapy: 400 mg daily for 1 week per month (2 pulses for fingernails, 3 for toenails) 2
- Monitor hepatic function tests, especially with continuous therapy >1 month 2
Common Pitfall to Avoid
Do not rely solely on normal liver enzymes to justify terbinafine use. The renal impairment is the determining factor here. The FDA label is explicit that terbinafine has not been adequately studied at this level of renal function, making its use off-label and potentially dangerous 1. While terbinafine is generally well-tolerated with only 0.04% serious adverse events in large surveillance studies 4, these studies did not specifically evaluate patients with significant renal impairment.
Clinical Bottom Line
With eGFR 50 mL/min, this patient falls into the unstudied population for terbinafine safety. Choose fluconazole with appropriate renal dose adjustment as the evidence-based alternative that maintains efficacy while providing a safer profile in renal impairment.